Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Colorcon
Boehringer Ingelheim
Baxter
Express Scripts

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,166,247

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,166,247
Title:Composition for inhalation
Abstract: The invention relates to a formulation comprising formoterol and budesonide for use in the treatment of respiratory diseases. The composition further contains HFA 227, PVP and PEG, preferably PVP K25 and PEG 1000.
Inventor(s): Govind; Nayna (Loughborough, GB), Marlow; Maria (Loughborough, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:15/427,425
Patent Claims: 1. A stable pharmaceutical composition comprising formoterol, budesonide or an epimer thereof, 1,1,1-2,3,3,3-heptafluoropropane (HFA 227), polyvinyl pyrrolidone (PVP) and polyethylene glycol (PEG).

2. The composition according to claim 1 wherein the PVP is present from about 0.0005 to about 0.05% w/w and the PEG is present from about 0.05 to about 0.35% w/w.

3. The pharmaceutical composition according to claim 1 in which the PVP is PVP K25.

4. The pharmaceutical composition according to claim 1 in which the PVP is present in an amount of 0.001% w/w.

5. The pharmaceutical composition according to claim 1 in which the PEG is PEG 1000.

6. The pharmaceutical composition according to claim 1 in which the PEG is present in an amount of 0.3% w/w.

7. The pharmaceutical composition according to claim 1 in which the formoterol is in the form of its fumarate dihydrate salt.

8. The pharmaceutical composition according to claim 1 in which the formoterol is in the form of its R, R-enantiomer.

9. The pharmaceutical composition according to claim 1 in which the budesonide or an epimer thereof is the 22R-epimer of budesonide.

10. The pharmaceutical composition according to claim 1 effective in the treatment of a respiratory disorder.

11. The pharmaceutical composition according to claim 1 effective in the treatment or asthma, rhinitis or COPD.

12. A method of treating a respiratory disorder in a mammal in need thereof, which comprises administering to the mammal an effective amount of the pharmaceutical composition according to claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Mallinckrodt
AstraZeneca
Colorcon
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.